Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $175.00

Key Points

• UBS raised Merck’s price target to $175 from $145 and maintained a “buy” rating, implying 15.34% upside from the previous close.
• Analyst sentiment remains broadly positive but mixed: 15 analysts rate Merck a Buy and eight rate it a Hold, producing a “Moderate Buy” consensus and an average target of $140.70; Jefferies recently downgraded the stock to Hold.
• Merck beat quarterly earnings and revenue expectations, reporting adjusted EPS of $(0.13) versus estimates of $(0.26) and revenue of $16.61 billion. Shares traded at $151.73, near their 12-month high, while insiders have sold roughly $30 million of stock over the past quarter.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its target price raised by analysts at UBS Group from $145.00 to $175.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. UBS Group's target price indicates a potential upside of 15.34% from the company's previous close.

Several other equities research analysts also recently commented on the stock. Jefferies Financial Group downgraded shares of Merck & Co., Inc. from a "strong-buy" rating to a "hold" rating in a research report on Wednesday. Scotiabank upped their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a "sector outperform" rating in a report on Tuesday, June 30th. Cantor Fitzgerald reissued a "neutral" rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Daiwa Securities Group raised Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 target price on the stock in a research report on Wednesday, August 12th. Finally, Royal Bank Of Canada reiterated a "sector perform" rating and issued a $150.00 target price (up from $142.00) on shares of Merck & Co., Inc. in a report on Thursday. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $140.70.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK traded down $0.47 during midday trading on Thursday, hitting $151.73. 6,239,130 shares of the company's stock were exchanged, compared to its average volume of 10,764,729. The company's 50 day moving average price is $126.86 and its 200 day moving average price is $120.74. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $153.50. The firm has a market capitalization of $374.34 billion, a PE ratio of 121.38, a price-to-earnings-growth ratio of 5.83 and a beta of 0.19. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.'s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the company's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares in the company, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the transaction, the executive vice president owned 46,613 shares in the company, valued at approximately $6,106,303. The trade was a 24.35% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company's stock.

Institutional Trading of Merck & Co., Inc.

Several institutional investors and hedge funds have recently bought and sold shares of MRK. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. in the 4th quarter worth $26,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. Graney & King LLC lifted its position in shares of Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company's stock worth $32,000 after buying an additional 200 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized mRNA cancer vaccine, intismeran, combined with Merck’s Keytruda, met the primary endpoint in a Phase 3 melanoma trial. The regimen significantly extended recurrence-free survival and reduced the risk of cancer spreading compared with Keytruda alone—the first positive late-stage result for an mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: The results strengthen Merck’s longer-term oncology pipeline and could help offset concerns about Keytruda’s expected patent expiration later this decade. The companies see potential use in thousands of high-risk melanoma patients, subject to additional data and regulatory approval targeted for 2027, while related trials are evaluating other cancers. Why this mRNA cancer vaccine is raising new treatment hope
• Positive Sentiment: Morgan Stanley upgraded MRK from “equal weight” to “overweight” and raised its price target to $179 from $116, implying substantial potential upside based on the reported valuation. Merck analyst upgrade
• Neutral Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating but lifted its target to $150 from $142, indicating limited near-term upside and a more cautious view of the vaccine opportunity. Royal Bank of Canada rating update
• Neutral Sentiment: Unusually heavy options activity, including a sharp increase in call purchases, suggests heightened speculative interest following the trial announcement, but does not necessarily indicate sustained fundamental demand.
• Negative Sentiment: Jefferies downgraded Merck from “strong-buy” to “hold,” reflecting potential profit-taking and uncertainty about the vaccine’s eventual approval, commercial adoption, pricing, and contribution relative to Keytruda’s mature revenue base. Jefferies rating update

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source